Cardiff Oncology (CRDF) Net Margin (2011 - 2026)
Cardiff Oncology (CRDF) posted Net Margin of 2972.43% for Q4 2025, up 68.33% sequentially from 9386.67% in Q3 2025, and up 483751.0% YoY from N/an in Q4 2024.
Cardiff Oncology (CRDF) Net Margin (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Net Margin for 15 years, with the latest figure at 2972.43% in Q4 2025.
- Quarterly Net Margin rose 483751.0% year-over-year to 2972.43% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7736.26% (down 109079.0% YoY) and the FY2025 annual result came in at 7736.26%, down 108106.0% from the prior year.
- Net Margin advanced to 2972.43% in Q4 2025 per CRDF's latest filing, from 9386.67% in the prior quarter.
- Over five years, Net Margin peaked at 2972.43% in Q4 2025 and troughed at 14863.51% in Q1 2022.
- A 5-year average of 8737.44% and a median of 7927.64% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2024: Net Margin tumbled 766212 bps in 2022, then jumped 864257 bps in 2024.
- Over 5 years, Net Margin stood at 7103.76% in 2021, then advanced by 4 bps to 6799.22% in 2022, then rose by 12 bps to 5989.1% in 2023, then slumped by 30 bps to 7809.93% in 2024, then surged by 62 bps to 2972.43% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 2972.43%, 9386.67%, and 11528.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -8,882.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,882.69% |
| Dec 31, 2025 | -2,972.43% |
| Sep 30, 2025 | -9,386.67% |
| Jun 30, 2025 | -11,528.10% |
| Mar 31, 2025 | -12,330.28% |
| Dec 31, 2024 | -7,809.93% |
| Sep 30, 2024 | -7,188.48% |
| Jun 30, 2024 | -7,229.45% |
| Mar 31, 2024 | -4,886.34% |
| Dec 31, 2023 | -5,989.10% |
| Sep 30, 2023 | -6,905.67% |
| Jun 30, 2023 | -10,329.63% |
| Mar 31, 2023 | -13,528.92% |
| Dec 31, 2022 | -6,799.22% |
| Sep 30, 2022 | -9,222.58% |
| Jun 30, 2022 | -11,482.42% |
| Mar 31, 2022 | -14,863.51% |
| Dec 31, 2021 | -7,103.76% |
| Sep 30, 2021 | -8,045.35% |
| Jun 30, 2021 | -9,945.59% |